Drugs /
ipilimumab
Overview
Biomarker-Directed Therapies
Clinical Trials
Ipilimumab has been investigated in 305 clinical trials, of which 271 are open and 34 are closed. Of the trials investigating ipilimumab, 3 are early phase 1 (3 open), 79 are phase 1 (70 open), 58 are phase 1/phase 2 (48 open), 135 are phase 2 (122 open), 3 are phase 2/phase 3 (3 open), 25 are phase 3 (23 open), 1 is phase 4 (1 open), and 1 is no phase specified (1 open).
EGFR Exon 19 Deletion, EGFR L858R, and EGFR L861Q are the most frequent biomarker inclusion criteria for ipilimumab clinical trials.
Melanoma, malignant solid tumor, and non-small cell lung carcinoma are the most common diseases being investigated in ipilimumab clinical trials [2].
Drug Details
References
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].
2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.